Edoxaban does not impact outcomes after TAVR vs. DAPT

WASHINGTON — In the ADAPT-TAVR trial of patients who had transcatheter aortic valve replacement and no indication for long-term anticoagulation, edoxaban did not improve leaflet thrombosis compared with dual antiplatelet therapy.There was also no difference between the edoxaban (Savaysa, Daiichi Sankyo) and DAPT groups in cerebral thromboembolism and neurological or neurocognitive function,

Related Keywords

Seoul ,Soult Ukpyolsi ,South Korea ,Montreal ,Quebec ,Canada ,United States ,Tennessee ,Washington ,Daewoong Pharm ,Daiichi Sankyo ,Chongkundang Pharm ,Megan Coylewright ,Edwards Lifesciences ,Erik Swain ,American College Of Cardiology Scientific Session ,Asan Medical Center ,Medtronic ,University Of Ulsan College Medicine ,Structural Heart Program At Erlanger Health System ,Breaking Clinical Trials ,American College ,Cardiology Scientific Session ,Abbott Vascular ,Medtronic Expand ,Duk Woo Park ,Ulsan College ,Rankin Scale ,Montreal Cognitive Assessment ,Structural Heart Program ,Erlanger Health System ,